GILD · News · 20261103N

Product / Drug Pipeline Progress

GILEAD SCIENCES, INC. · 2026-11-03 · Importance 17 · Surprise 24

Gilead plans to present more than 50 studies at HIV Glasgow 2026, including late-breaking clinical data and real-world evidence. The presentations will cover HIV prevention, treatment, and cure research, with a focus on twice-yearly lenacapavir and once-weekly oral options. Featured data include the PURPOSE 5 PrEP study, BICSTaR real-world evidence on Biktarvy, and ARTISTRY and ISLEND trial results for novel treatment combinations.

Key facts

• Gilead will present over 50 studies at HIV Glasgow 2026 from November 8-11, including late-breaking clinical data and real-world evidence. source
• Gilead will present PURPOSE 5 PrEP data, BICSTaR real-world effectiveness data for Biktarvy, and results from the ARTISTRY and ISLEND trials for novel treatment combinations. source
• Gilead's HIV Glasgow 2026 presentations will cover twice-yearly lenacapavir and once-weekly oral options for HIV prevention, treatment, and cure research. source